Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Prescribing information
Prescribing information for Oman, Bahrain, Kuwait, Qatar, UAE
Augmentin 1 g
Prescribing information
Augmentin 156 mg
Prescribing information
Augmentin 312 mg
Prescribing information
Augmentin 457 mg
Prescribing information
Augmentin Infant drops
Prescribing information
Augmentin 1 g
Prescribing information
Augmentin 156 mg
Prescribing information
Augmentin 228 mg
Prescribing information
Augmentin 312 mg
Prescribing information
Augmentin 375 mg
Prescribing information
Augmentin suspension 228 mg/5 ml and 457 mg/5 ml
Prescribing information
Augmentin 625 mg tablets
Prescribing information
Augmentin drops
Prescribing information
Augmentin ES
Prescribing information
Augmentin 1 g
Prescribing information
Augmentin 156 mg
Prescribing information
Augmentin 228 mg
Prescribing information
Augmentin 312 mg
Prescribing information
Augmentin 457 mg
Prescribing information
Augmentin drops
Prescribing information
Augmentin ES
Prescribing information
Augmentin 1 g
Prescribing information
Augmentin 156 mg
Prescribing information
Augmentin 228 mg
Prescribing information
Augmentin 312 mg
Prescribing information
Augmentin 457 mg
Prescribing information
Augmentin 625 mg
Prescribing information
Augmentin drops
Prescribing information
Augmentin ES
Prescribing information
Augmentin 1 g
Prescribing information
Augmentin 156 mg
Prescribing information
Augmentin 228 mg
Prescribing information
Augmentin 312 mg
Prescribing information
Augmentin 375 mg
Prescribing information
Augmentin 457 mg
Prescribing information
Augmentin 625 mg
Prescribing information
Augmentin drops
Prescribing information
Augmentin ES
Prescribing information
-
MDI 4.6x fewer patients
made a critical error* with Ellipta vs. MDI
(Ellipta 13%; MDI 60%, p<0.001)10Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)¹⁰
Adapted from van der Palen et al. 201610*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
**This study assessed critical errors in the most common type of MDI (metered–dose inhaler) where shaking prior to use is required. The most common critical error with an MDI was poor actuation and inhalation coordination10
-
ACCUHALER 8.8x fewer patients
made a critical error* with Ellipta vs. Accuhaler
(Ellipta 5%; Accuhaler 44%, p<0.001)10Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
-
TURBUHALER 5.5x fewer patients
made a critical error* with Ellipta vs. Turbuhaler
(Ellipta 8%; Turbuhaler 44%, p<0.001)10Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
-
HANDIHALER 3.4x fewer patients
made a critical error* with Ellipta vs. Handihaler
(Ellipta 14%; Handihaler 48%, p<0.001)10Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
-
BREEZHALER 3.5x fewer patients
made a critical error* with Ellipta vs. Breezhaler
(Ellipta 13%; Breezhaler 46%, p<0.001)10Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
Need help with this product?
PM-XX-XXX-WCNT-XXXXXX Date of preparation: XXXX XXXX
